Blood

Article	Citations
Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma	2339
Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML	2149
Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma	1187
Hemophagocytic Lymphohistiocytosis Clinical Features and Outcomes: Single Institution Case Series	299
Development of a Fast and Quantitative FLT3-TKD Mutation Prototype Using Lab in a Cartridge™ Technology	244
SDC2 Expression Is Increased in Myeloma Cells in Response to Loss of Pro-Survival Surface Proteins, CD28 and CD86	233
Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma	200
Impact of Chronic Disease and Its Burden on Aspects of Quality of Life in a Unique Sub-Population of Myeloproliferative Neoplasm Patients	199
Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML	199
Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma	192
Impacts of the COVID-19 Pandemic on Assessment of M-Protein and Free Light Chain Levels in Patients with Multiple Myeloma	187
A-two to the rescue	178
Collins PJ, Fox CP, George L, et al. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. Blood. 2021;137(2):203-215.	173
Germline Variants in MDM4 Cause a Disorder of p53 Dysregulation and Insufficient Telomere Maintenance	172
Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib	166
Antiaging for Ph-like ALL: targeting senescence	163
The chromatin accessibility landscape of pediatric AML	158
A New Class of Synthetic Type-B Polycyclic Polyprenylated Acylphloroglucinols (PPAP-B) Overcomes Venetoclax-Resistance in Acute Myeloid Leukemia (AML)	154
Contactless edema via plasmin	150
Heparin or nonheparin anticoagulants for VITT	150
Waking up exhausted BCMA-specific T cells in myeloma	150
GADD45A: a key tumor suppressor in AML subtypes	145
Baby steps in managing CVAD-related thrombosis	139
MDM2 inhibition augments GVL effect	138
Blast phagocytosis	135

High-mobility-group protein A1 in MPN progression	133
Renewing your HBO1 subscription	132
Role and timing of chromosome deletions in multiple myeloma	132
An AID to follicular lymphoma transformation	130
Towards a standard of care in transplant for WAS	130
Unexpected parvovirus B19 infection in a patient with multiple myeloma	130
Pediatric B-acute lymphoblastic leukemia presenting with a mass: an underrecognized association	130
Bleeding tendency with corkscrew hair	129
PI3king apart a rare disease with targeted therapy	126
Peripheral erythrophagocytosis in paroxysmal cold hemoglobinuria	125
A rare glimpse of Fessas bodies in a patient with β-thalassemia major postsplenectomy	123
Proton export takes charge of proliferation	123
Breaking T-cell tolerance in the immune system	122
A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders	120
C1 Inhibitor Deficiency Results in Increased Activation of Coagulation and Enhanced Venous Thrombosis	120
Targeting PKCα decreases iron overload in diabetes	120
Identification of Pyroptosis-Related Signature and Development of a Novel Prognostic Model in Diffuse Large B-Cell Lymphoma	118
The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway	118
Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology	117
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience	117
Dynamics and Predictive Value of T-Cell Chimerism after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide	116
Treatment Patterns and Outcomes in Adolescent and Young Adults with Nodular Lymphocyte Predominant Hodgkin Lymphoma: An Impact Cohort Population-Based Study	116
Restless Legs Syndrome (RLS) in Patients (pts) with Polycythemia Vera (PV): Is Iron Deficiency (ID) the Only Culprit?	115
The Role of N-Acetylcysteine Amide (NACA) As Prophylactic Treatment for Acute Graft-Versus-Host Disease	114
Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy	113
The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can	113
Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study	113
Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Ri	112
Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma	111
Profiling the E3 Ubiquitin Ligase Landscape in Normal and Sickle Red Blood Cells	109
Antiviral Response and HIV-1 Inhibition in Sickle Cell Disease	109
White Matter Injury in Sickle Cell Mice Is Associated with Reduced Neurocognitive Function and Activation of Astrocytes	108
Retrospective Comparison of Patients with Chronic Lymphocytic Leukemia Receiving BTK Inhibitors Versus Obinutuzumab/Venetoclax As Frontline Therapy	108
Efficiency and Safety of Avatrombopag in the Management of Thrombocytopenia with TPO or Tpora Ineffective：a Prospective, Single Arm, Exploratory Clinical Study	108
A Multimodal Single Cell Atlas of Human Tonsils Reveals New Insights into T and B Cell Differentiation	106
Perception of Marijuana Use, Risk/Benefits in Sickle Cell Disease	106
Derivation and External Validation of Clinical Risk Assessment Model for Cancer Associated Thrombosis in Two Unique U.S. Healthcare Systems	105
Suppressed Expression of ASCT1 Contributes to the Maintenance of Leukemia Stemness Via the Enhancement of Antioxidant Capacity	104
No Specific Factors Associated with Risk of Readmission for Rebound Pain in Children with Sickle Cell Disease and Asthma Treated with Systemic Corticosteroids	104
Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma	104
Changes in Symptoms, Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents	104
Changes in the T Helper Cell Compartment during Treatment with the BTK Inhibitor Acalabrutinib	104
Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population	103
P-Selectin Blockage Potentiates the Inhibiting Effects of Inflammasome Cytokine Neutralization on Leukocyte Recruitment in an In Vivo Model of Acute Sickle Cell Vaso-Occlusion	102
Reticulocytes Are an Unappreciated Risk Factor for RBC Alloimmunization at the Donor and Recipient Levels	101
The Novel Nano-Formulation of the HDAC Inhibitor, Romidepsin, for the Treatment of Relapsed, Refractory Peripheral T-Cell Lymphoma	100
Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry	100
Proteotranscriptomic Strategy to Discover Acute Myeloid Leukemia Immunotherapy Targets	98
Profiling of Heparin-Induced Thrombocytopenia Antibodies in Thai People Who Received ChAdOx1 Ncov-19 Vaccination	97
Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial	97

Analysis of Liquid Biopsy Performance for the Detection of Lymphoma in Dogs with a Focus on Recurrent Copy Number Variants in Matched Plasma and Lymph Node Aspirates: Implications for a Comparative On	96
Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo	96
Real-World Outcomes and Cardiac Implications of FLT3 Inhibitors in Acute Myeloid Leukemia	96
Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Ther	96
Risk of Intracranial Hemorrhage with Direct Oral Anticoagulants (DOACs) Versus Low Molecular Weight Heparin (LMWH) in Primary and Secondary Brain Cancers: An up-to-Date Meta-Analysis of Comparative St	95
Real-World Experience of Venetoclax Combination Therapy in Patients with Acute Myeloid Leukemia (AML): A Single-Institution Retrospective Study in a Middle-Income Country	94
Genomic Landscape of IgM MGUS and Asymptomatic Waldenström Macroglobulinemia Patients	94
The Profiling of Circulating Tumor DNA Liquid Biopsy in Children and Adolescent Lymphoblastic Lymphoma	93
Clinical Significance and Molecular Characteristics of Circulating Plasma Cells in Multiple Myeloma	92
Dominant-Negative VPS4A Mutations Causing Congenital Dyserythropoietic Anemia Disrupt Iron Trafficking of Terminal Erythropoiesis	92
Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes	91
Characterization of the Human Mesenchymal Stromal Compartment in Normal Homeostasis and Acute Myeloid Leukemia at the Level of the Single Cell	91
The Expression of SREBF1 Inducing By Dexamethasone Promotes Bone Marrow Mesenchymal Stromal Cells Differentiate to Adipocytes to Attract and Protect the Residual T-Cell Acute Lymphoblastic Leukemia Ce	90
CRISPR-Cas9 Genome Editing of Primary Chronic Lymphocytic Leukemia Cells	89
Cellular Therapy Product Viability during Long Term Cryopreserved Storage	87
Empagliflozin Modifies Neutrophils' Subsets in Patients with Glycogen Storage Disease Type Ib By Increasing Mature Neutrophils and Decreasing Immature Neutrophils	87
Interim PET-CT Scan to Improve Risk Modeling for Patients with Extranodal Natural Killer/T-Cell Lymphoma Treated with Non-Anthracycline Containing L-Asparaginase Based Regimen	86
Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects	85
Values and Preferences Towards Antithrombotic Therapy in Patients with Myeloproliferative Neoplasms: A Qualitative Study	85
Identification of Biomarkers As Predictors of Patient-Reported Outcomes in Persons with Multiple Sclerosis Given Autologous Hematopoietic Stem Cell Transplantation	84
Establishment of High Titer Baboon Endogenous Retrovirus Envelope Pseudotyped Lentiviral Vector Production Protocol Focusing on Syncytium Formation and Exfoliation	84
Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group	84
ICOS and OX40 Signaling Optimization Improves CAR-T Cell Persistence in Preclinical Models	83
A Study to Evaluate the Utility and Appropriateness of Diagnostic Workup for Leukocytosis in the Hematology Clinic	83
A Rare Case of Spontaneous Tumor Lysis Syndrome As a Consequence of Forgone Treatment in Multiple Myeloma	83
Phenotype and Natural History of ELANE and NON ELANE Severe Congenital Neutropenia in Italy: Data from the National Registry	83
Impact of HLA-B Leader Mismatching on Outcomes after Haploidentical Transplantation with Antithymocyte Globulin	82
Clinical Features and Prognosis of Double Primary Malignant Neoplasms in Patients with Non-Hodgkin Lymphoma	82
Anti CD19 CAR-T Cell Therapy Can Clear Minimal Residual Disease in Bone Marrow of Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphomas	82
Relative Telomeric Length of Bone Marrow Cells at Diagnosis and Its Association with Minimal Residual Disease in Juvenile Acute Lymphoblastic Leukemia	82
Delayed Neutrophil Engraftment in Autologous Transplant Patients with Very High CD34+ Cell Collections in a Single Apheresis	82
The Cost of Cellular Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis	81
Single-Cell Multi-Omic and Spatial Analysis of Nodal B Cell Non-Hodgkin Lymphomas Reveals Plasticity in B Cell Maturation As a Driver of Intratumor Heterogeneity	81
A Single-Center Study of Patients with Isolated Acquired Clotting Factors Deficiency: Clinical Features, Treatments and Prognosis	80
Effect of Hydroxyurea on Patient with High Fetal Hemoglobin Expression	80
Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice	79
Analysis of Clinical Cytokine Panel Profiles As Diagnostic and Prognostic Biomarkers in Pediatric Hyperinflammatory Conditions	79
Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study	78
EFS24 Failure, BRD4 Expression, and TP53 Are Linked to Reduced CDKN1A Expression in DLBCL and May be Targeted By Single-Agent Protac ARV-825 or in Synergistic Combination with the CDK4/6 Inhibitor Abe	78
Concerns about Prognostic Meaning of Quantitative PET Analysis in Classical Hodgkin Lymphoma	78
Benchmarking Paediatric Sickle Cell Care in Australia	78
Targeting Cell Adhesion Molecules in IDH Mutant Myeloid Malignances	77
Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy	76
Immune Profiling of MM Microenvironment at Single-Cell Resolution	76
AI-Enabled Screening for Drug Repurposing in Monoclonal Gammopathy of Undetermined Significance	76
A Mixed Methods Study to Examine the Influence of Structural Racism on Treatment in Acute Myeloid Leukemia	76
Shear Stress Promotes Platelet Surface Desialylation, Platelet Count Drop, and Microvesiculation: Do Platelets Need to be Sugar-Coated?	76
Protease Activated Receptor-1 (PAR-1) Inhibition By Parmodulin 2, but Not Vorapaxar, Protects Sickle Cell Mice from Heme-Induced Acute Chest Syndrome	76
A Novel Ptpn11E76K/Npm1cA Murine Model of AML Identifies a Unique Immune Population Relevant to Human Disease	75
Prospective Study of the Usefulness of Liquid Biopsy in Patients with Unknown Fever Suspected of Malignant Lymphoma	75
Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study	75
Long Term Follow up of Elderly Patients with Classical Hodgkin's Lymphoma: An Analysis of the Texas Cancer Registry	75
Chronic Myeloid Leukemia Failed Second Generation Tyrosine Kinase Inhibitor Patients' Molecular Interrogation Using Next Generation Sequencing	74
Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes	74
Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis	74
Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis	74
Predicting Platelet Age Using Artificial Intelligence Techniques	73
Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study	73
Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphom	73
Blood. 2023;142(22) and 142(25).	73
Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study	72
Core transcription balancing erythropoiesis	72
Synthetic Lethal Interactions with IRAK4 Inhibition in Myeloid Malignancies	71
Castleman's Disease:Clinicopathological Characteristics of a Cohort of Hispanic Patients	71
Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation	71
Early Onset of Smoldering Disease Correlates with Rapid Progression to Symptomatic Multiple Myeloma	71
Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients	71
Characteristics and Clinical Outcomes of Patients with Acute Myeloid Leukemia with TP53 Mutations - a Single Center Experience	70
Sting Activation Improves T-Cell Engaging Immunotherapy of Acute Myeloid Leukemia	70
Constructing a Machine Learning-Based Rating Model to Predict the Outcome of GCSF Mobilization of Hematopoietic Stem Cells in Peripheral Blood	70
Prospective Evaluation of Patient-Reported Outcome up to 10 Years after Allogeneic Stem Cell Transplantation Using FACT-G/BMT and EORTC-QLQ30 Questionnaires	69
A Retrospective Study Evaluating the Association of Qualitative and Quantitative Aspects of Vaso-Occlusive Crises (VOC) with Length of Hospital Stay in Children with Sickle Cell Disease Hospitalized f	69
Telomere Length in Survivors of Childhood Hematologic Malignancies	69
Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study	69
Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen	69
Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement	69
Utility of Bone Marrow Biopsies for Basal Stratification and Response Assessment in a Large Series of Real Life Follicular Lymphoma Patients	68
Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients	68
No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis	67
Non-Canonical Double Mutant DNMT3A mutations: Clinical and Biological Significance in Myeloid Neoplasms	67

Metformin-Induced Ferroptosis Is a Therapeutic Vulnerability in IDH2-Mutant AML Linked to Metabolic Rewiring Towards Fatty Acid Oxidation	66
Loss of EFL1 Which Causes a Shwachman-Diamond Syndrome Reduces Cell Proliferation and Alters Transcriptional Profiling during Neutrophil Differentiation	66
Digital Polymerase Chain Reaction (dPCR) Versus Flow Cytometry (FC), a Validation Study for CAR-T Cell Product Optimal Detection	66
Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma	65
Deciphering VITT’s dangerous code	65
MiRNA29B Induces Fetal Hemoglobin through Targeting DNMT3 and MYB in Vitro and In Vivo in Preclinical Townes Sickle Cell Mice	65
HSCs with the “SUPER” power to make blood forever	64
Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine	64
Total Hip Arthroplasty in Patients with Sickle Cell Disease: A National Database Study	64
Caregiver Perspectives on Housing, Finances and Employment Post-Allogeneic Hematopoietic Cell Transplant	64
Evaluation of Immune Reconstitution in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Cevostamab in Phase I Study GO39775	64
Risk of Infections in Multiple Myeloma in the Era of Novel Agents, a Population-Based Study Based on 8672 Multiple Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry	64
Prognostic Impact of Skeletal Muscle Index and Vitamin D in Diffuse Large B-Cell Lymphoma	64
Treatment of Acute Lymphoblastic Leukemia with PDT Regimen Improves the Prognosis of Newly Diagnosed Central Nervous System Leukemia	64
Neurotropin Alleviates Bortezomib-Induced Neurotoxicity Via Microglial Neuroinflammation	63
Fatal Pulmonary Embolism, Fatal Bleeding and Intracranial Hemorrhage with Systemic and Catheter-Directed Thrombolysis in Intermediate-High and High-Risk Pulmonary Embolism: A Systematic Review with Me	62
Targeting Sumoylation Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment	62
Soluble PD-L1 Predicts Poor Outcome and Disease Progression in Patients with De Novo Myelodysplastic Syndromes	62
Genome-Wide Methylome and Transcriptome Profiling of Acute Myeloid Leukemia Derived Bone Marrow Mesenchymal Cells Identify Age Group Specific Biological Pathway Dysregulation in the Bone Marrow Microe	62
Distinct Immune and Molecular Profiles of Hepatitis-Associated Aplastic Anemia	61
Exploring Regional Challenges and Solutions to Appropriate and Equitable Care for Patients with Chronic Lymphocytic Leukemia	61
Fetal Hemoglobin Decrease during Voxelotor Treatment	61
Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation	61
Implementing Quality Improvement to Morbidity and Mortality Conferences: Focusing on Action Plans By Closing the Loops with Timely Follow Ups	61
Disease Monitoring in Acute Myeloid Leukemia with CLEC2A qRT-PCR	60
Routine Computed Tomography before Pediatric Hematopoietic Stem Cell Transplantation and Association with Length of Stay and Early Non-Relapse Mortality	60
Neighborhood Disadvantage Is Associated with Inferior Overall Survival for Acute Myeloid Leukemia Patients Treated with Standard Intensive Induction	60
The Prognostic Value of Common Cardiovascular Biomarkers in the Survival of Patients with DLBCL	60
Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease	60
Renal Sub-Study (GEM-KyCyDex): Cystatin C Improves the Proficiency of Creatinine Alone in the Detection and Management of Myeloma-Related Renal Impairment	60
Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)	60
Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype	60
Analysis of CD58 As a Predictive Marker of Morphologic Response to Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia	60
Real-World Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis at a Single Center	59
Epic: A Second Interim Analysis of the Non-Interventional, Observational Multi-Centre Cohort Study of Patients with Chronic Lymphocytic Leukaemia Treated with First-Line Acalabrutinib through the UK E	59
Identification of Healthy Donor Phenotypic and Functional Signatures That Predict Allogeneic, Hypoimmune CD19-Directed CAR T Cell Potency	59
Hemolysis Induced Induction of Matrix Metalloproteinases in Sickle Cell Disease	59
Synergy between Iron Deficiency and Inflammation Adversely Affects Pregnancy	59
C17ORF58 Is Upregulated in Peripheral T-Cell Lymphomas and Encodes a Protein Critical for Survival of PTCL Cells	59
Extended Thromboprophylaxis in Patients Hospitalized with COVID-19 at Time of Discharge from the Hospital Is Not Associated with an Improvement in Quality of Life: Results from the Activ 4c Clinical T	59
The DNA Sensor AIM2 Determines B Cell Fate after BCR Activation in Chronic Graft-Vs-Host Disease	59
Identification of a Relapse Signature in t(8;21) Pediatric AML	58
Outcomes of Patients Treated at First Transplant Center in Dubai, UAE	58
Overall Survival in Advanced Stage Mantle Cell Lymphoma after Early Autologous Stem Cell Transplantation with Cisplatin, Etoposide, Cytarabine and Melphalan (PEAM) As a Conditioning Regimen	58
Dysfunctional Stromal Pathways Mark Early Changes within the Bone Marrow Microenvironment in JAK2 V617F-Driven Model of Myeloproliferative Neoplasm	58
Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients	58
A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies	58
Efficacy of Daratumumab in 34 Patients with Newly Diagnosed Multiple Myeloma in Real World Study	57
Contemporary Multiple Myeloma Treatment Patterns Among HCPs and Concordance with Expert Recommendations: Analysis of an Interactive Online Decision Support Tool	57
Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the R	57
When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study	57
May-Thurner Syndrome Should be Explored As a Possible Existing Risk Factor in Pediatric Patients Presenting with Non-Central Venous Line Associated Deep Vein Thrombosis	57
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01	57
Effects of Intermittent Fasting on Patients with Immune Thrombocytopenia (ITP) Receiving TPO-RA : Multicenter Mixed-Design Study	57
Improved Risk Prediction in DLBCL By Combining Clinical and PET Features with Interim PET Assessment	56
Advances in Acute Myeloid Leukemia Classification: A Comparative Analysis of Who-HAEM4R, Who-HAEM5, and International Consensus Classification	56
CD38-Directed, Single-Chain T Cell-Engager Targets Leukemia Stem Cells through IFNγ-Induced CD38 Expression	56
The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia	56
Del(20q) As a Somatic Gene Rescue in Adult Patients: Can Germline Mutations Other Than SBDS be Found in Affected Patients?	55
Derivation of a Risk Prediction Model for Venous Thromboembolism in Adult Patients with Acute Myeloid Leukemia	55
Reduced Intensity Condition of ATG Based Haploidentical Hematopoietic Stem Cell Transplantation in Elderly or Unfit Patients	55
Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study By the EBMT Acute Leukemia Working Party	55
The Efficacy and Prognosis of Advanced Myelodysplastic Syndrome in Children	55
Outcomes of Incorporating IV Daratumumab for the Treatment of AL Amyloidosis in Real World Patients from a Multicenter Registry in Latin America	55
Cytotoxic Stress Transiently Increases the Contribution of Platelet-Biased Hematopoietic Stem Cells to Platelet Production	55
Autologous Hematopoietic Stem Cell Transplantation May Overcome the Adverse Impact of IKZF1 on the Prognosis of B-ALL in CR1 with No Detectable Minimal Residual Disease	55
Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the	54
Scalp Cooling to Prevent Hair Loss in Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation	54
Determinants and Clinical Impact of Time to Plasma Exchange in Patients with Immune Thrombotic Thrombocytopenic Purpura	54
Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant	54
Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma	54
Transplant Associated Thrombotic Microangiopathy: Acomprehensive Review and Local Experience	54
CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists	53
Safety and Efficacy of Autologous HSCT in Nine Patients with AIDS-Related Non-Hodgkin Lymphoma	53
Role of Tubulin Detyrosination in Platelet Biogenesis	53
Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study	53
Informed Representation of Persons Living with Sickle Cell Disease in the US and Factors That Influence Clinical Trial Participation	53
Sequential Conditioning Regimen with Thiotepa, Clofarabine and Busulfan (TEC/CloB2A2) and Post-Transplant Cyclophosphamide in Adults with Refractory AML: A Retrospective Monocentric Study	53
Acquired Von Willebrand Syndrome, Epidemiology, Laboratory Findings and Molecular Alterations on Classic Myeloproliferative Neoplasms in Mexican Population	53
Clinical Characterization of Hepatic Light Chain Amyloidosis in the Chinese Population: A Single-Center Retrospective Analysis	53
Primary Pulmonary Diffuse Large B-Cell Lymphoma - a Rare Case Report	52
Assessment of Circulating Retinol Binding Protein-4 Levels in Patients with Compound Heterozygosity for Hb S and β-Thalassemia	52
Impact of IV Contrast Exposure during Vaso-Occlusive Crisis on Sickle Cell Disease (SCD)	51
Identifying and Managing Patients with Life-Threatening Hematology Disorders By Doing Telemedicine Inpatient Hematology Consults in Underserved Hospitals	50
Α-Globin Lentiviral Vectors for Hematopoietic Stem Cell Gene Therapy of α-Thalassemia	50
The Kinetics of FLT3L during Induction Chemotherapy for Pediatric Acute Lymphoblastic Leukemia Suggests a Novel Clinical Diagnostic and Treatment Strategy	50
Increased Environmental Temperature Is an Emerging Health Risk That Correlates with Rates of Acute Lymphoblastic Leukemia in Europe	50
A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma	49
A Real-World Pharmacovigilance Analysis of Chemotherapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia	49
A Single-Center Study of Patients with Isolated Acquired Clotting Factor Deficiency: Clinical Features, Treatments, and Prognosis	49
Donor T Cell Infusions Limit Novel Immune Checkpoint Therapy in Pancreatic Cancer: Implications for Adoptive T Cell Therapy	49
Impact of Survivorship Care Plans (SCP) on Mortality in a Contemporary Cohort of Pediatric Patients Diagnosed with a Blood Cancer	49
Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy	49
Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study	49
Selinexor in Combination with Azacitidine (AZA) in Patients with Myelodysplastic Syndrome (MDS): A Real-World Retrospective Study	49